When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report

BACKGROUND: Long-term survival with durable response remains possible in the area of targeted therapies. Discontinuation of sunitinib could improve quality of life and reduce treatment costs in metastatic renal cell carcinoma with long-term disease stabilization. We discuss a case of successful inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Sbitti, Yassir, Debbagh, Adil, Slimani, Khaoula, Mahi, Mohamed, Errihani, Hassan, Ichou, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859488/
https://www.ncbi.nlm.nih.gov/pubmed/29554941
http://dx.doi.org/10.1186/s13256-018-1597-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859488/
https://www.ncbi.nlm.nih.gov/pubmed/29554941
http://dx.doi.org/10.1186/s13256-018-1597-z

Ejemplares similares